Latest News and Press Releases

New York, USA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight The hemophilia market is expected to...

Pune, India, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Coagulation or clotting is the process by which blood turns from a liquid into a gel and forms a blood clot. This potentially leads to hemostasis,...

New York, USA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Hemophilia A Market to Exhibit Growth at a Remarkable CAGR During the Study Period (2019-2032) | DelveInsight  The current therapeutic landscape...

LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the...

Seattle, Aug. 24, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global hemophilia gene therapy market is estimated to be valued at US$ 330.9 million in 2022 and is expected to...

Las Vegas, USA, March 29, 2022 (GLOBE NEWSWIRE) -- Global Hemophilia A Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight  Hemophilia A Pipeline constitutes 40+...

Selbyville, Delaware, March 01, 2022 (GLOBE NEWSWIRE) -- Hemophilia treatment market revenue is projected to reach USD 16 billion by 2028, according to a new research report by Global Market...

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...

~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of AMT-060 Maintained in All...